Ticker
Reporting Basis
Period
From
To
Form Type
Report Format
Update Type


ACORDA THERAPT   FYE=12 (December)

Annual - Income Statement - Company Specific

Fiscal period2020201920182017201620152014201320122011
Period End Date12/31/202012/31/201912/31/201812/31/201712/31/201612/31/201512/31/201412/31/201312/31/201212/31/2011
Net Sales124.83180.74459.74549.75493.36466.11373.29310.32282.38256.27
Royalty revenue13.1411.6711.6929.4817.1917.4919.1317.0614.381.91
Milestone revenue15.00----------------25.00
Gross sales-Zanaflex--------------------
Less: discounts and allowances--------------------
Revenue- License revenue------9.069.069.069.069.069.069.06
Grant revenue--------------------
Total Revenue152.97192.41471.43588.29519.60492.66401.48336.43305.81292.24
Cost of sales33.5134.8597.64111.32107.4892.3079.9866.0157.0164.18
Less: cost of license revenue------0.630.630.630.630.630.632.38
Gross Profit----------------248.17225.67
Goodwill impairment4.13277.56--296.76------------
Amortization of intangible asset30.7625.641.6723.76------------
Research and development23.0160.08106.38166.11203.44149.2173.4753.8853.8842.11
General and Administrative152.58192.85172.25235.44235.44205.63201.81185.55168.69148.51
Sales and marketing--------------------
Loss on assets held for sale(57.90)------------------
Asset impairment------------(6.99)------
Change in fair value of derivative liability39.96------------------
Change in fair value of acquired contingent consideration30.8986.94(55.00)(40.90)(8.60)(10.90)(2.20)------
Total Operating Expenses231.04504.04432.95821.10555.58458.67365.09306.07280.21257.18
Operating Income (Loss)(78.08)(311.63)38.49(232.81)(35.98)33.9936.3930.3725.6035.05
Interest and amortization of debt discount expense30.5721.8721.6018.6616.5315.479.292.171.883.57
Interest income0.824.173.520.140.340.440.670.670.550.55
Other income (loss)0.170.010.02(0.54)9.900.410.23--(0.01)(0.02)
Gain on debt extinguishment--55.07----------------
Loss before taxes(107.67)(274.25)20.42(251.89)(42.27)19.3728.0128.8624.2732.02
Provision for income taxes(8.07)(1.28)(13.26)(28.53)(6.67)8.3110.3412.42(130.69)1.41
Cumulative effect of change in accounting principle--------------------
Consolidated Net Income (Loss)--------(35.60)11.0617.6716.44154.96--
Net loss attributable to noncontrolling interest--------(0.99)----------
Beneficial conversion feature, accretion of issuance costs, preferred dividends, and fair value of warrants issued to co--------------------
Net income (loss) Available to Common Shareholders(99.59)(272.97)33.68(223.36)(34.62)11.0617.6716.44154.9630.61
Net Earnings Per Share (Basic)(12.32)(34.43)4.32(29.15)(4.56)1.562.582.4623.584.68
Net Earnings Per Share (Diluted)(12.32)(34.43)4.26(29.15)(4.56)1.502.522.3423.044.56
Weighted Average Shares Outstanding (Basic)8.087.937.847.677.547.046.866.706.586.50
Weighted Average Shares Outstanding (Diluted)8.087.937.897.677.547.277.096.956.726.68